PT  - JOURNAL ARTICLE
AU  - Khan, Fasihul A
AU  - Stewart, Iain
AU  - Saini, Gauri
AU  - Robinson, Karen A.
AU  - Jenkins, R Gisli
TI  - An individual participant data meta-analysis of prognostic blood biomarkers in IPF
AID  - 10.1101/2021.03.30.21254621
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.30.21254621
4099  - http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254621.short
4100  - http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254621.full
AB  - Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with variable disease trajectory. Blood biomarkers reflecting disease severity that can accurately predict outcomes are urgently needed. Through systematic review and meta-analysis, we evaluate the prognostic potential of matrix-metalloproteinase-7 (MMP-7) and other frequently studied blood biomarkers in patients with IPF.Methods Electronic databases were searched on 12th November 2020 to identify prospective studies reporting outcomes in patients with untreated IPF, stratified according to at least one pre-specified biomarker, measured at either baseline or change over three months. Individual participant data (IPD) was sought for studies investigating MMP-7 as a prognostic factor. The primary outcome was overall mortality, with secondary outcomes including disease progression, defined as >10% relative FVC decline or death.Results 29 studies reporting outcomes from 3950 IPF participants were included, investigating a total of 16 biomarkers. IPD from MMP-7 studies was available for eleven cohorts. Baseline MMP-7 levels were associated with increased mortality (adjusted HR1.23 per SD increase, 95%CI 1.03;1.48, I2=64.3%) and disease progression (adjusted OR1.27 per SD increase, 95%CI 1.11;1.46, I2=5.9%), but change in MMP-7 over three-months was not associated with any of the measured outcomes. There was insufficient data for quantitative analysis in non-MMP7 studies, and whilst many biomarkers showed an association with clinical outcomes, replication of effects across studies was weak.Conclusion Baseline MMP-7 levels were associated with an increased risk of overall mortality and disease progression in patients with untreated IPF. The evidence for other biomarkers is currently insufficient with further studies needed.Competing Interest StatementAll authors have no competing interests.RGJ reports personal fees and other from Biogen, personal fees from Galapagos, other from Galecto, personal fees and other from GlaxoSmithKline, personal fees from Heptares, personal fees and other from MedImmune, personal fees from Boehringer Ingelheim, personal fees from Pliant, personal fees from Roche/InterMune, personal fees from MedImmune, personal fees from PharmAkea, personal fees from Bristol Myers Squibb, personal fees from Chiesi, personal fees from Roche/Promedior, other from RedX, other from NuMedii, other from Nordic Biosciences, personal fees from Veracyte, outside the submitted work; and is supported by a National Institute of Health Research Professorship (NIHR ref: RP-2017-08-ST2-014).Clinical TrialPROSPERO registration number: CRD42019120402Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019120402 Funding StatementFunding: FK/IS are supported by the Nottingham National Institute for Health Research (NIHR) Biomedical Research Centre. RGJ is supported by an NIHR Research Professorship (RP-2017-08-ST2-014).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMeta-analysis of published data